GlassScriptPhysician profile
Angela S Chan
NPI 1649441338
$15,422.84
in general payments reported to CMS, 2019-2025
36 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,391 · 2020: $2,809 · 2021: $3,278 · 2022: $2,648 · 2023: $1,788 · 2024: $1,356 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,197.56 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,770.15 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,743.16 | 2019-2024 | Trulance, Xifaxan |
| Kowa Pharmaceuticals America, INC. | $1,442.80 | 2019-2025 | Livalo, Seglentis, Zoryve |
| Janssen Pharmaceuticals, INC | $1,299.58 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.44 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $1,068.54 | 2019-2023 | |
| Novo Nordisk INC | $987.50 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $649.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $463.41 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $450.10 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Optinose US, INC. | $383.57 | 2020-2024 | |
| Amarin Pharma, INC. | $371.81 | 2019-2022 | |
| Radius Health, INC. | $369.02 | 2019-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $356.54 | 2021-2025 | |
| Horizon Therapeutics Plc | $342.14 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $330.51 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $281.15 | 2021-2025 | Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $231.24 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $228.63 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $216.57 | 2024-2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $204.23 | 2021-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $185.85 | 2023-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $165.31 | 2019-2024 | |
| Arbor Pharmaceuticals, INC. | $164.35 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $101.75 | 2021-2023 | Eliquis |
| Pfizer INC. | $88.76 | 2019-2021 | |
| Corcept Therapeutics | $73.03 | 2025 | Korlym |
| Abbott Laboratories | $58.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.61 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $36.74 | 2024 | Gemtesa |
| Ardelyx, INC. | $27.61 | 2024 | Ibsrela |
| Circassia INC. | $26.05 | 2019 | |
| Esperion Therapeutics, INC. | $24.99 | 2021 | |
| Redhill Biopharma INC. | $22.95 | 2023 | Talicia |
| Mylan Specialty L.P. | $21.93 | 2021 | |
| Smith+Nephew, INC. | $16.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.